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Abstract 
Background: Familial high blood cholesterol (hypercholesterolemia) is a common disease that involves many 
complications for patients. The aim of this study is to investigate the effects of cholesterol-lowering drugs 
(Gemfibrozil and Atorvastatin) on the level of serum Vitamin D. Materials and Methods: In this study, the 25-
hydroxy vitamin D levels were evaluated in 65 women between 30-55 years of age. After receiving drug information 
of patients, cholesterol-lowering medication; Gemfibrozil and Atorvastatin were prescribed by a specialist, then 
vitamin D and cholesterol levels were measured following 9 month treatment. Also 30 patients consumed vitamin D 
supplements plus medicine regularly. Results: In the first stage, vitamin D levels in subjects are quite normal but 
their cholesterol levels were higher than normal. In the second stage, vitamin D levels were measured after 9 months 
use of Gemfibrozil and Atorvastatin. Accordingly, cholesterol levels decreased significantly due to the use of blood 
cholesterol-lowering drugs (p=0.021). Also, in this stage the level of vitamin D showed a severe and significant 
reduction (p=0.041). However, there were no significant reductions in vitamin D in 30 women who consumed 
vitamin D supplements plus medicine (p=0.073). Conclusion: It seems that taking cholesterol-lowering medicines 
have reduced the amount of vitamin D. With long-term use of medications, bone diseases such as osteoporosis can 
be predicted in these individuals. Therefore, taking supplements and food rich in vitamin D during the use of these 
drugs is recommended. 
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     Congenital hypercholesterolemia is characterized 
by high levels of LDL.  Approximately 2% to 15% 
who suffer from a high hypercholesterolemia, have a 
family-defective gene. The genetic cause and 
pathogenicity of hypercholesterolemia is known to be 
about 20%-40% autosomal dominant. 
Hypercholesterolemia occurs by mutation in LDLR, 
APOB, PCSK9, and APOE genes (1, 2).  
Vitamin D is a fat-soluble vitamin, which is 
supplied through dietary intake, vitamin D 
supplements and exposure to sunlight. Vitamin D has 
a hormonal activity that is well known in cell 
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differentiation, reproduction, immune system 
regulation, parathyroid hormone suppression, calcium 
and phosphorus homeostasis and bone metabolism (3, 
4). The absorption of calcium in the intestine is the 
primary target of vitamin D and in this path indirectly 
enhances the intermixture of calcium in the bone. 
Vitamin D deficiency may result in the decline of 
bone quality and cause bone softness, while a sharp 
decrease in vitamin D, increases the risk of 
osteoporosis and bone fractures. In recent decades, 
research has also shown that there are many non-
skeletal diseases associated with vitamin D (5). 
Vitamin D can indirectly contribute to lipid profile 
changes. The Increasing serum levels of vitamin D 
are associated with inhibition of parathormone levels 
in the serum, and studies have shown that 
parathormone can reduce lipolysis (6). Enhancing 
calcium levels may reduce the production or secretion 
of liver triglyceride (7). In general, calcium intake 
lead to reduction of absorption of fatty acids by 
creating a calcium-fatty acid complex (8). Moreover,  
Vitamin D is expected to reduce levels of cholesterol, 
triglycerides, LDL and HDL by increasing calcium 
absorption (9). However, the effect of intestinal 
calcium on the absorption of fat is very low and it has 
no significant effect on the serum lipid profile 
changes (10). 
Statins reduce blood cholesterol and are 
involved in inflammation of cardiovascular disease 
(11). Atorvastatin is a statin or an inhibitor of the 3-
HMG-COA (3-Hydroxymethylglutaryl Coenzyme A 
reductase) enzyme and a blood fat regulating agent 
that acts on plasma lipids. Due to the use of this drug 
for the treatment of hyperlipidemia, LDL, 
triglycerides and apolipoprotein B levels have been 
reduced and in opposite HDL levels have been 
increased (12, 13). Gemfibrozil is also a cholesterol-
lowering drug and its use decreases the plasma 
concentration of VLDL and increases the plasma 
HDL. Although this drug may slightly reduce total 
cholesterol and LDL, but its use in patients with high 
triglycerides, with type IV high blood fat, often 
results in a significant increase in LDL (14). 
In regards to the high prevalence of familial 
hypercholesterolemia and also the fact that familial 
hypercholesterolemia patients should be using 
cholesterol-lowering drugs such as Gemfibrozil and 
Atorvastatin for the long time, the aim of this study 
was to evaluate the effect of Gemfibrozil and 
Atorvastatin drugs on the levels of serum Vitamin D. 
Methods 
Study subjects. This study was performed on 
65 women between the ages of 30-55 years, during 
2014 in Bonab. The inclusion criteria were having 
congenital hypercholesterolemia and no consumption 
of cholesterol-lowering drugs (Gemfibrozil and 
Atorvastatin). The subjects were selected from among 
the referrals to Bonab Medical Laboratories. After 
verifying the disease by a specialist physician and 
completing the consent, peripheral blood sample from 
the venous vein was obtained from all subjects. 
ELISA analysis. Sampling in fasting state 
(after 8 to 10 hours of fasting) was performed 
between 8:00 and 10:00 am. Blood tubes were 
centrifuged for 10 minutes at 1500 g to provide blood 
serum. The serum samples were stored at freezer 
temperature and kept at a temperature of -79 °C until 
tests were performed. After blood sampling, samples 
were taken to measure vitamin D and blood 
cholesterol using ELISA kit instructions and done by 
ELISA reader Lab System Multi Scan (Italy). The 
samples were then read and evaluated by optical 
absorption by an ELISA reader with a wavelength of 
490 NM. In the following step, Gemfibrozil and 
Atorvastatin were prescribed by a specialist physician 
for patients and these drugs were used by these people 
for 9 months. Overall, 65 women surveyed, 30 were 
randomly selected as the case group and received 
supplements containing vitamin D along with 
medicine. The remaining 35 women were considered 
as control group and only used cholesterol-lowering 
drugs. After 9 months, blood samples were taken 
from the people studied again and blood levels of 
vitamin D and cholesterol were measured by ELISA 
method. 
Statistical analysis. Finally, the results 
obtained from two stages of ELISA tests were 
analyzed by SPSS software version 23. They were 
expressed as a mean ±standard deviation for 
quantitative variables and the number and percentage 
of qualitative values. The level of significance was 
considered as P<0.05. 
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Results 
This study was performed in two stages. In the 
first stage, vitamin D and cholesterol were studied in 
the subjects. The results of this part of study revealed 
that vitamin D levels in subjects are quite normal. 
Also, because of high congenital cholesterol problems 
and not taking cholesterol-lowering drugs, their 
cholesterol levels were higher than normal (Table 1 
and Table 2).  
In the second stage, vitamin D levels were 
measured after 9 months use of Gemfibrozil and 
Atorvastatin prescribed by a specialist. Blood 
cholesterol measurements at this stage showed that 
blood cholesterol levels decreased significantly due to 
the use of blood cholesterol-lowering drugs 
(p=0.021). Also, in this stage the level of vitamin D 
showed a severe and significant reduction (p=0.041). 
However, there were no significant reductions in 
vitamin D in 30 women who consumed vitamin D 
supplements plus medicine (p=0.073) (Table 1 and 
Table 2). 
Discussion 
In the first stage, the cholesterol and vitamin D 
levels were evaluated in normal women. In the second 
stage, blood cholesterol has been significantly 
reduced caused by the inhabitation of the synthesis of 
HMG-CoA reductase that was due to the consumption 
of Gemfibrozil and Atorvastatin. The level of vitamin 
D also decreased within this group. On the other 
hand, women who took vitamin D supplements 
showed a relatively small decrease in vitamin D. The 
gene is continually associated with the levels of 
vitamin D circulation (15, 16), and in turn, the level 
of vitamin D is associated with lipid levels in adults 
(17). Interestingly, RXRG, a key gene in the pathway 
of vitamin D, is located in the chromosomal region 
1q21-Q23, closely associated with high congenital 
cholesterol. The most common fatty acid metabolism 
disorder is atherogenic and is characterized by several 
hyperlipidemia phenotypes in which the level of LDL 
is high (18). Therefore, this evidence from studies 
supports that our findings on vitamin D associated 
with gene and lipid profiles in high congenital 
cholesterol.  
In a prospective study by Anderson et al. In 
2010, involved more than 40,000 people, the 
association between low levels of vitamin D and 
various risk factors for cardiovascular disease such as 
type 2 diabetes, high blood pressure and high 
congenital cholesterol and brain stroke have been 
proved. Vitamin D plays an important role on the 
lipid profile of genetic diversity (19). Vitamin D, 
whether made in the skin or taken with food, after 
entering the bloodstream bonds to the vitamin D 
binding Protein (DBP) that is responsible for 
transporting this vitamin in metabolic pathways and 
target tissues (20, 21). Vitamin D indirectly plays role 
in changing the lipid profile. Increasing serum levels 
of vitamin D is associated with parathormone 
Table1. Mean on cholesterol level of serum in the case and control group in the first and second stages of the study. 
P value Second Stage First Stage 
Variable 
Cholesterol Level (mg/dL) 
0.011 179.65 ± 45.5 251.07 ± 39.1 Case Group (n=30) 
0.032 187 ± 39.1 243.49 ± 41.5 Control Group (n=35) 
- 0.49 0.45 P value 
 
Table2. Mean of Vitamin D level of serum in the case and control group in the first and second stages of the study. 
P value Second Stage First Stage 
Variable 
Vitamin D Level (mg/dL) 
0.073 36.66 ± 6.5 41.43 ± 8.5 Case Group (n=30) 
0.021 17.38 ± 6.9 39.93 ± 6.8 Control Group (n=35) 
- 0.003 0.81 P value 
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inhibition. In vitro studies have shown that 
parathormone can reduce lipolysis (22). On the other 
hand, vitamin D also plays a role in regulating 
calcium homeostasis. Zitterman et al. showed that 
vitamin D can reduce production or decrease liver 
secretion of triglyceride by increasing calcium levels 
(7). Calcium is one of the minerals that can be bonded 
to bile acids and cause fecal excretion of it. The 
production of new bile acids from cholesterol 
decreases its serum levels (10). Therefore, vitamin D 
is expected to reduce cholesterol levels by increasing 
calcium uptake, regarding the fact that the effect of 
intestinal calcium is very low in fat absorption and is 
less likely to have a significant effect on serum lipid 
profiles (23). Jorde et al., have provided 22 cross-
sectional review studies on the relationship between 
vitamin D deficiency and lipid profiles with a 
minimum sample size of 500 people and 10 
interferential studies with vitamin D supplements and 
placebo-controlled. In all cross-sectional studies, 
serum levels of 25-hydroxyvitamin D have a direct 
correlation with HDL levels and an inverse 
association with triglyceride, which improves the 
ratio of total cholesterol to LDL-C and HDL-C. On 
the contrary, some Interventional studies have 
reflected positive and negative correlations in this 
regard, so that the same result cannot be obtained 
(17). In this study, increased cholesterol levels played 
role in increased vitamin D levels, but Gemfibrozil 
and Atorvastatin consumption significantly reduced 
vitamin D levels.  
Rejnmark et al showed that 82 healthy 
menopausal women treated with simvastatin 40 
mg/day or placebo for one year, at the start of 
treatment were examined at weeks 25 and 56. The 
results of this study showed that Gemfibrozil and 
Atorvastatin, not only are regarded as cholesterol-
lowering drugs, and being of the statin family, but 
also reduce vitamin D (22).   
In addition, a cell culture study using human 
fibroblasts demonstrated that vitamin D is a key 
enzyme in the synthesis of cholesterol due to 3HMG-
COA (3-hydroxymethylglutaryl coenzyme A 
reductase) inhibition. In the present study, with 
HMG-COA enzyme inhibition, the amount of vitamin 
D was significantly reduced (24). The limitations of 
this study are as follows; Due to the cross-sectional 
nature of the study, it is not possible to determine the 
cause and effect relationship between the variables of 
the study. Studies have shown that in obese 
individuals with more fat mass, the serum level of 25-
hydroxylamine vitamin D decreases and so-called 
vitamin D in the adipose tissue is trapped. One of the 
limitations of this study is the lack of measurement of 
body composition, including body fat mass. Also, the 
serum level of apolipoprotein was not measured. 
Conclusion 
Our findings demonstrated that taking 
cholesterol-lowering medicines have reduced the 
amount of vitamin D. With long-term use of 
medications, bone diseases such as osteoporosis can 
be predicted in these individuals. Therefore, taking 
supplements and food rich in vitamin D during the 
use of these drugs is recommended. 
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